Page 8 - Northstar Medical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress
itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals
NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease
March 16, 2021 NorthStar Medical Radioisotopes, LLC announced organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business. The new structure enables NorthStar to advance its efforts in radioisotope development and commercialization planning in parallel with its ongoing expansion programs for increased U.S. molybdenum-99 (Mo-99) capacity and production.
In conjunction with other organizational changes, NorthStar has appointed Dave Wilson, RPh., BCNP, as Vice President, Advanced Radiopharmaceutical and Therapeuti
Posted on 407
NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and therapeutic treatments, today announced that the U.S. Food and Drug Administration (FDA) has approved its application for producing Mo-99 from concentrated Mo-98 (cMo-98) and related software updates for the RadioGenix® System (technetium Tc 99m generator). Processing of cMo-98 targets increases production capacity of the important medical radioisotope, molybdenum-99 (Mo-99), up to four times above that of current NorthStar technology, and enables NorthStar to provide customers with higher activity source vessels, which will support enhanced radiopharmacy efficiencies. FDA approval was granted through a Prior Approval Supplement (PAS) to NorthStar’s original RadioGenix® System (technetium Tc 99m generator) New Drug Application, which was approved in 2018. The R